By Dr Ben Kong

Journal articles

Alexander M; Rogers J; Parakh S; Mitchell P; Clay TD; Kao S; Hughes BGM; Itchins M; Kong BY; Pavlakis N; Solomon BJ; John T, 2024, 'Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme', Internal Medicine Journal, 54, pp. 1087 - 1096, http://dx.doi.org/10.1111/imj.16348

Brown LJ; Khou V; Brown C; Alexander M; Jayamanne D; Wei J; Gray L; Chan WY; Smith S; Harden S; Mersiades A; Warburton L; Itchins M; Lee JH; Pavlakis N; Clarke SJ; Boyer M; Nagrial A; Hau E; Pires da Silva I; Kao S; Kong BY, 2024, 'First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study', Frontiers in Oncology, 14, http://dx.doi.org/10.3389/fonc.2024.1305720

Agar MR; Nowak AK; Hovey EJ; Barnes EH; Simes J; Vardy JL; Wheeler HR; Kong BY; Leonard R; Hall M; Tim E; Spyridopoulos D; Sim HW; Lwin Z; Dowling A; Harrup R; Jennens R; Kichenadasse G; Dunlop T; Gzell C; Koh ES, 2023, 'Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study', BMJ Supportive and Palliative Care, 13, pp. 354 - 362, http://dx.doi.org/10.1136/spcare-2022-004119

Wei JQ; Yuile A; Itchins M; Kong BY; Li BT; Pavlakis N; Chan DL; Clarke SJ, 2023, 'Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis', Biomedicines, 11, http://dx.doi.org/10.3390/biomedicines11071827

Trinder SM; McKay C; Power P; Topp M; Chan B; Valvi S; McCowage G; Govender D; Kirby M; Ziegler DS; Manoharan N; Hassall T; Kellie S; Heath J; Alvaro F; Wood P; Laughton S; Tsui K; Dodgshun A; Eisenstat DD; Endersby R; Luen SJ; Koh ES; Sim HW; Kong B; Gottardo NG; Whittle JR; Khuong-Quang DA; Hansford JR, 2023, 'BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1154246

Sim H-W; Wachsmuth L; Barnes EH; Yip S; Koh E-S; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; McDonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.', Neurooncol Adv, 5, pp. vdad124, http://dx.doi.org/10.1093/noajnl/vdad124

Halkett GKB; Breen LJ; Berg M; Sampson R; Sim HW; Gan HK; Kong BY; Nowak AK; Day BW; Harrup R; James M; Saran F; Mcfarlane B; Tse C; Koh ES, 2022, 'Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers', Current Oncology, 29, pp. 9928 - 9955, http://dx.doi.org/10.3390/curroncol29120781

Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C, 2022, 'Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multiarm randomised clinical trial for people affected by glioblastoma', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058107

Kong BY; Carter C; Nowak AK; Hovey E; Lwin Z; Haghighi N; Gan HK; Sim HW; Ziegler DS; Barton K; Parkinson J; Leonard R; Khasraw M; Foote M, 2022, 'Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective', Asia-Pacific Journal of Clinical Oncology, 18, pp. 259 - 266, http://dx.doi.org/10.1111/ajco.13606

Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK, 2021, 'LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study', BMJ Open, 11, http://dx.doi.org/10.1136/bmjopen-2021-054075

Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', Neuro-Oncology, 23, pp. vi106 - vi107, http://dx.doi.org/10.1093/neuonc/noab196.420

Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'RTID-05. THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', Neuro-Oncology, 23, pp. vi193 - vi194, http://dx.doi.org/10.1093/neuonc/noab196.767

Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M, 2021, 'The gut microbiome and cancer immunotherapy: Can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy?', Cancers, 13, http://dx.doi.org/10.3390/cancers13194824

Fromm PD; Silveira PA; Hsu JL; Papadimitrious MS; Lo TH; Ju X; Kupresanin F; Romano A; Hsu WH; Bryant CE; Kong B; Abadir E; Mekkawy A; M. McGuire H; Groth BFDS; Cunningham I; Newman E; Gibson J; Hogarth PM; Hart DNJ; Clark GJ, 2020, 'Distinguishing human peripheral blood CD16⁺ myeloid cells based on phenotypic characteristics', Journal of Leukocyte Biology, 107, pp. 323 - 339, http://dx.doi.org/10.1002/JLB.5A1119-362RRR

Bryant CE; Sutherland S; Kong B; Papadimitrious MS; Fromm PD; Hart DNJ, 2019, 'Dendritic cells as cancer therapeutics', Seminars in Cell and Developmental Biology, 86, pp. 77 - 88, http://dx.doi.org/10.1016/j.semcdb.2018.02.015

Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ, 2019, 'On the other side: Manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy', Frontiers in Oncology, 9, http://dx.doi.org/10.3389/fonc.2019.00050

Hsu JL; Bryant CE; Papadimitrious MS; Kong B; Gasiorowski RE; Orellana D; McGuire HM; Groth BFDS; Joshua DE; Ho PJ; Larsen S; Iland HJ; Gibson J; Clark GJ; Fromm PD; Hart DNJ, 2018, 'A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission', OncoImmunology, 7, http://dx.doi.org/10.1080/2162402X.2017.1419114

Eroglu Z; Zaretsky JM; Hu-Lieskovan S; Kim DW; Algazi A; Johnson DB; Liniker E; Kong B; Munhoz R; Rapisuwon S; Gherardini PF; Chmielowski B; Wang X; Shintaku IP; Wei C; Sosman JA; Joseph RW; Postow MA; Carlino MS; Hwu WJ; Scolyer RA; Messina J; Cochran AJ; Long GV; Ribas A, 2018, 'High response rate to PD-1 blockade in desmoplastic melanomas', Nature, 553, pp. 347 - 350, http://dx.doi.org/10.1038/nature25187

Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA, 2017, 'Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma', Clinical Cancer Research, 23, pp. 5024 - 5033, http://dx.doi.org/10.1158/1078-0432.CCR-16-0698

Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS, 2017, 'Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial', The Lancet Oncology, 18, pp. 1202 - 1210, http://dx.doi.org/10.1016/S1470-2045(17)30428-X

Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2017, 'Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''', British Journal of Cancer, 116, pp. e15, http://dx.doi.org/10.1038/bjc.2017.59

Naidoo J; Wang X; Woo KM; Iyriboz T; Halpenny D; Cunningham J; Chaft JE; Segal NH; Callahan MK; Lesokhin AM; Rosenberg J; Voss MH; Rudin CM; Rizvi H; Hou X; Rodriguez K; Albano M; Gordon RA; Leduc C; Rekhtman N; Harris B; Menzies AM; Guminski AD; Carlino MS; Kong BY; Wolchok JD; Postow MA; Long GV; Hellmann MD, 2017, 'Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy', Journal of Clinical Oncology, 35, pp. 709 - 717, http://dx.doi.org/10.1200/JCO.2016.68.2005

Hwang SJE; Kong BY; Chou S; Wakade D; Carlino MS; Fernandez-Penas P, 2017, 'Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis', Case Reports in Medicine, 2017, http://dx.doi.org/10.1155/2017/5462929

Liniker E; Menzies AM; Kong BY; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2016, 'Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma', OncoImmunology, 5, http://dx.doi.org/10.1080/2162402X.2016.1214788

Kong BY; Menzies AM; Saunders CAB; Liniker E; Ramanujam S; Guminski A; Kefford RF; Long GV; Carlino MS, 2016, 'Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy', Pigment Cell and Melanoma Research, 29, pp. 572 - 577, http://dx.doi.org/10.1111/pcmr.12503

Bowyer S; Prithviraj P; Lorigan P; Larkin J; McArthur G; Atkinson V; Millward M; Khou M; Diem S; Ramanujam S; Kong B; Liniker E; Guminski A; Parente P; Andrews MC; Parakh S; Cebon J; Long GV; Carlino MS; Klein O, 2016, 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy', British Journal of Cancer, 114, pp. 1084 - 1089, http://dx.doi.org/10.1038/bjc.2016.107

Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS, 2016, 'Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma', Melanoma Research, 26, pp. 202 - 204, http://dx.doi.org/10.1097/CMR.0000000000000232

Kong BY; Carlino MS; Menzies AM, 2016, 'Biology and treatment of BRAF mutant metastatic melanoma', MELANOMA MANAGEMENT, 3, pp. 33 - 45, http://dx.doi.org/10.2217/mmt.15.38

Hwang SJE; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P, 2016, 'Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort', Journal of the American Academy of Dermatology, 74, pp. 455 - 461.e1, http://dx.doi.org/10.1016/j.jaad.2015.10.029

Liniker E; Kong B; Menzies AM; Cooper A; Ramanujam S; Lo S; Kefford RF; Fogarty GB; Guminski A; Wang TW; Carlino MS; Hong A; Long GV, 2015, '3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma', European Journal of Cancer, 51, pp. S664 - S664, http://dx.doi.org/10.1016/s0959-8049(16)31821-4

Liniker E; Kong B; Menzies AM; Cooper AJ; Kefford RF; Fogarty GB; Guminski A; Carlino MS; Wang TW; Long GV; Hong A, 2015, 'Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma', International Journal of Radiation Oncology*Biology*Physics, 93, pp. E635 - E635, http://dx.doi.org/10.1016/j.ijrobp.2015.07.2168

Clarke RJ; Apell HJ; Kong BY, 2007, 'Allosteric effect of ATP on Na⁺,K⁺-ATPase Conformational kinetics', Biochemistry, 46, pp. 7034 - 7044, http://dx.doi.org/10.1021/bi700619s

Kong BY; Clarke RJ, 2004, 'Identification of Potential Regulatory Sites of the Na⁺,K ⁺-ATPase by Kinetic Analysis', Biochemistry, 43, pp. 2241 - 2250, http://dx.doi.org/10.1021/bi0355443

Buhagiar KA; Hansen PS; Kong BY; Clarke RJ; Fernandes C; Rasmussen HH, 2004, 'Dietary cholesterol alters Na⁺/K⁺ selectivity at intracellular Na⁺/K⁺ pump sites in cardiac myocytes', American Journal of Physiology - Cell Physiology, 286, http://dx.doi.org/10.1152/ajpcell.00016.2003

Hansen PS; Buhagiar KA; Kong BY; Clarke RJ; Gray DF; Rasmussen HH, 2002, 'Dependence of Na⁺-K⁺ pump current-voltage relationship on intracellular Na⁺, K⁺, and Cs⁺ in rabbit cardiac myocytes', American Journal of Physiology - Cell Physiology, 283, http://dx.doi.org/10.1152/ajpcell.01343.2000

Conference Papers

Sim HW; Wachsmuth L; Barnes EH; Yip S; Koh ES; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; Mcdonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma', in Neuro-Oncology Advances, http://dx.doi.org/10.1093/noajnl/vdad124

Kong B; Sim H-W; Amanuel B; Day B; Buckland M; Verhaak R; Yip S; Johns T; Lwin Z; Rosenthal M; Nowak AK; Barnes EH; Scott AM; Parkinson J; Jeffree R; Lourenco RDA; Lau P; Whittle J; Hovey E; Cher L; Kichendasse G; Hall M; Robinson C; Thomas M; Giardina T; Tu E; Khasraw M; Koh E-S; Gan H, 2021, 'LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 106 - 106, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000757356200422&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kong B; Sim H-W; Koh E-S; Gan H; Barnes EH; Yip S; Nowak AK; Lau P; Cuff K; Khoo E; Lwin Z; Cooper A; Dowling A; Linton A; Harrup R; Dunlop T; Hovey E; Parkinson J; Jeffree R; Hall M; Tu E; Andrew D; Simes J; Gedye C, 2021, 'THE MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA) TRIAL', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, MA, Boston, pp. 193 - 194, presented at 26th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO), MA, Boston, 18 November 2021 - 21 November 2021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000757356200769&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sutherland S; Abadir E; Kong B; Stockler M; Mahon K; Silveira P; Horvath L; Clark G, 2019, 'Novel Targets for an In Vivo DC Anti-Prostate Cancer Vaccine', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kim J; Kong B; Lo T-H; Papadimitrous MS; Hsu J; Fromm P; Kaufman K; Buckland M; Clark G; Hart D, 2018, 'A COMBINATORY IMMUNOTHERAPY AGAINST BRAIN TUMOUR: BLOOD DENDRITIC CELL BASED VACCINE THERAPY WITH CHECKPOINT INHIBITOR(S)', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, LA, New Orleans, pp. 94 - 95, presented at 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference, LA, New Orleans, 14 November 2018 - 18 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000460646300396&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kong B; Kim J; Fromm P; Bui KT; Linton A; Kaufman K; Beale P; Buckland M; Clark G, 2018, 'THE IMMUNE LANDSCAPE OF BLOOD DENDRITIC CELLS IN GLIOBLASTOMA MULTIFORME: IMPLICATIONS FOR DC VACCINATION COMBINED WITH CHECKPOINT INHIBITION', in NEURO-ONCOLOGY, OXFORD UNIV PRESS INC, LA, New Orleans, pp. 132 - 132, presented at 23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference, LA, New Orleans, 14 November 2018 - 18 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000460646300555&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hwang SJE; Park J; Wakade D; Byth K; Chou S; Kong BY; Carlino MS; Fernandez-Penas P, 2016, 'Cutaneous toxicities of anti-programmed cell death1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 use in metastatic melanoma patients', in AUSTRALASIAN JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL, pp. 10 - 10, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387333500026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kong BY; Saunders CAB; Liniker E; Ramanujam S; Kefford RF; Guminski A; Menzies AM; Long GV; Carlino MS, 2015, 'FDG-PET METABOLIC ACTIVITY IN METASTATIC MELANOMA AFTER LONG-TERM TREATMENT WITH ANTI-PD-1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 40 - 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357957300003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page